Mark A Findeis
- The role of amyloid beta peptide 42 in Alzheimer's diseaseMark A Findeis
Satori Pharmaceuticals Incorporated, 222 Berkeley Street, Suite 1040, Boston, MA 02116, USA
Pharmacol Ther 116:266-86. 2007..Such compounds are now reaching clinical evaluation to determine how they may be of benefit in the treatment of AD...
- Peptide inhibitors of beta amyloid aggregationMark A Findeis
Praecis Pharmaceuticals Incorporated, 830 Winter Street, Waltham, MA 02451 1420, USA
Curr Top Med Chem 2:417-23. 2002..This article reviews efforts to adapt the structure of Abeta to the design and testing of peptide-based inhibitors of Abeta polymerization of interest as potential AD therapeutics...
- Beta-amyloid 1-42 lowering agent for Alzheimer's DiseaseMARK FINDEIS; Fiscal Year: 2006..This compound will be of interest for other neurological disorders where Ap-related toxicity may be a contributing factor. [unreadable] [unreadable]..
- NC/OFQ analogs as ORL1 agonists to promote gut motilityMARK FINDEIS; Fiscal Year: 2005..Compounds will be evaluated using both in vitro and in vivo assays to select a candidate for preclinical evaluation for use as a prokinetic agent to treat postoperative ileus. ..